首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N,N'-bis(salicylidene)-1,2-propanediamine as complexation reagent.
【24h】

High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N,N'-bis(salicylidene)-1,2-propanediamine as complexation reagent.

机译:溶剂萃取和N,N'-双(水杨基)-1,2-丙二胺作为络合剂,高效液相色谱法测定顺铂药物给药后癌症患者血液和尿液中的铂。

获取原文
获取原文并翻译 | 示例
           

摘要

A high performance liquid chromatographic (HPLC) procedure has been developed for the determination of cisplatin, based on the pre-column derivation of platinum(II) with reagent N,N'-bis(salicylidene)-1,2-propanediamine (H2SA2pn). The neutral platinum complex was extracted, concentrated in an organic solvent and then injected (5 microl) on a reverse phase HPLC column, Varian Micro-Pak SP C-18, 5 microm (150 mm x 4.0 mm i.d.). The complex was eluted isocratically using a ternary mixture of methanol/acetonitrile/water (40/30/30, v/v/v) at a flow rate of 1.0 ml/min and was determined by a UV detector set at 254 nm after elution. A detection limit was found to be 4.0 ng per injection. The amounts of platinum in blood serum and urine of cancer patients after administration of cisplatin were observed in a range of 221-298 ng/ml and 43-97 ng/ml with relative standard deviation (R.S.D.) of 3.6-4.6% and 3.5-4.8%, respectively. Preliminary metabolism profiles of Pt concentrations in blood and urine from the patients were established.
机译:基于试剂N,N'-双(水杨基)-1,2-丙二胺(H2SA2pn)对铂(II)的柱前衍生,开发了一种用于测定顺铂的高效液相色谱(HPLC)方法。提取中性铂络合物,浓缩在有机溶剂中,然后(5微升)注入反相HPLC柱,Varian Micro-Pak SP C-18,5微米(150mm×4.0mm,内径)。使用甲醇/乙腈/水(40/30/30,v / v / v)的三元混合物等度洗脱,流速为1.0 ml / min,并通过设置在254 nm的UV检测器进行测定。发现每次进样的检出限为4.0 ng。服用顺铂后,癌症患者血清和尿液中的铂含量为221-298 ng / ml和43-97 ng / ml,相对标准偏差(RSD)为3.6-4.6%和3.5-分别为4.8%。建立了患者血液和尿液中Pt浓度的初步代谢曲线。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号